Translate Bio (TBIO) Prices 9M Share Common Offering at $10/Sh

Translate Bio, Inc. (NASDAQ: TBIO) today announced the pricing of its underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $10.00 per share, for aggregate gross proceeds of $90 million, before deducting underwriting discounts and commissions and offering expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being sold by Translate Bio. The offering is expected to close on September 20, 2019, subject to the satisfaction of customary closing conditions.

Citigroup, Jefferies and SVB Leerink are acting as joint book-running managers for the offering. The shares are being offered by Translate Bio pursuant to an effective shelf registration statement that was filed with the Securities and Exchange Commission (SEC) on July 3, 2019 and declared effective by the SEC on July 19, 2019.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• TaskUs names Rishabh Khemka as CFO, effective June 2026
• Deep Fission raises $40M in public offering on Nasdaq